DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,755 filers reported holding DANAHER CORPORATION in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,469,562 | -20.5% | 74,444 | -23.1% | 0.86% | -14.0% |
| Q2 2023 | $23,241,067 | -19.0% | 96,838 | -15.0% | 1.00% | -23.9% |
| Q1 2023 | $28,697,857 | -8.2% | 113,862 | -3.3% | 1.32% | -11.8% |
| Q4 2022 | $31,252,986 | -4.5% | 117,749 | -7.1% | 1.50% | -6.6% |
| Q3 2022 | $32,738,000 | +6.4% | 126,751 | +4.5% | 1.60% | +18.0% |
| Q2 2022 | $30,759,000 | -15.3% | 121,326 | -2.0% | 1.36% | +3.7% |
| Q1 2022 | $36,320,000 | +11.5% | 123,821 | +25.1% | 1.31% | +17.2% |
| Q4 2021 | $32,561,000 | +41.9% | 98,967 | +31.3% | 1.12% | +30.6% |
| Q3 2021 | $22,954,000 | +17.2% | 75,399 | +3.3% | 0.86% | +13.7% |
| Q2 2021 | $19,589,000 | +109.4% | 72,996 | +75.7% | 0.75% | +88.0% |
| Q1 2021 | $9,353,000 | +1111.5% | 41,554 | +1095.5% | 0.40% | +1079.4% |
| Q4 2020 | $772,000 | +17.9% | 3,476 | +14.2% | 0.03% | +13.3% |
| Q3 2020 | $655,000 | +139.9% | 3,043 | +97.2% | 0.03% | +114.3% |
| Q2 2020 | $273,000 | +25.8% | 1,543 | -1.5% | 0.01% | +7.7% |
| Q1 2020 | $217,000 | -15.6% | 1,566 | -6.4% | 0.01% | 0.0% |
| Q4 2019 | $257,000 | +22.4% | 1,673 | -31.7% | 0.01% | +8.3% |
| Q3 2017 | $210,000 | – | 2,450 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |